Testing effectiveness (Phase 2)Study completedNCT04672330
What this trial is testing
Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma
Who this might be right for
Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma
RenJi Hospital 16